Correction: “Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial”(The Lancet Diabetes & Endocrinology (2020) 8(7) (582–593), (S2213858720301625), (10.1016/S2213-8587(20)30162-5));Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

The Lancet Diabetes and Endocrinology

Volumn 8, Issue 7, 2020, Pages 582-593

  Cherney, David Z I ^a   Dekkers, Claire C J ^b   Barbour, Sean J ^c   Cattran, Daniel ^a   Abdul Gafor, Abdul Halim ^d   Greasley, Peter J ^e   Laverman, Gozewijn D ^f   Lim, Soo Kun ^g   Di Tanna, Gian Luca ^h   Reich, Heather N ^a   Vervloet, Marc G ⁱ   Wong, Muh Geot ^h,j   Gansevoort, Ron T ^b   Heerspink, Hiddo J L ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^e ASTRAZENECA R AND D   (Sweden)

^f Regional Hospital ZGT   (Netherlands)

^g UNIVERSITY OF MALAYA   (Malaysia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ Amsterdam Infection and Immunity   (Netherlands)

^j ROYAL NORTH SHORE HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DAPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FRACTURE; GENITAL TRACT INFECTION; HEALTH HAZARD; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SCREENING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION; URINARY TRACT INFECTION; ADOLESCENT; ADVERSE EVENT; CANADA; FOLLOW UP; GLOMERULUS FILTRATION RATE; INCIDENCE; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; BIOMARKERS; CANADA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; YOUNG ADULT;

EID: 85086365019     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(20)30217-5     Document Type: Erratum

References (30)

1. Heerspink, HJL, Desai, M, Jardine, M, Balis, D, Meininger, G, Perkovic, V, Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
2. Wiviott, SD, Raz, I, Bonaca, MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
3. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
4. Perkovic, V, Jardine, MJ, Neal, B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 (2019), 2295–2306.
5. Mosenzon, O, Wiviott, SD, Cahn, A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7 (2019), 606–617.
6. Neuen, BL, Ohkuma, T, Neal, B, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol 30 (2019), 2229–2242.
7. Neuen, BL, Young, T, Heerspink, HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7 (2019), 845–854.
8. Cannon, C, Perkovic, V, Agarwal, R, et al. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial. Circulation 141 (2020), 407–410.
9. Cherney, DZI, Perkins, BA, Soleymanlou, N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
10. van Bommel, EJM, Muskiet, MHA, van Baar, MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 97 (2020), 202–212.
11. Cherney, DZ, Odutayo, A, Aronson, R, Ezekowitz, J, Parker, JD, Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC review topic of the week. J Am Coll Cardiol 74 (2019), 2511–2524.
12. Rajasekeran, H, Reich, HN, Hladunewich, MA, et al. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Am J Physiol Renal Physiol 314 (2018), F412–F422.
13. Ma, Q, Steiger, S, Anders, HJ, Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol Rep, 5, 2017, e13228.
14. Zhang, Y, Thai, K, Kepecs, DM, Gilbert, RE, Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One, 11, 2016, e0144640.
15. Zhang, Y, Nakano, D, Guan, Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 94 (2018), 524–535.
16. Levey, AS, Stevens, LA, Schmid, CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
17. Bröchner-Mortensen, J, A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30 (1972), 271–274.
18. Du Bois, D, Du Bois, EF, A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17 (1916), 863–871.
19. Cherney, DZI, Zinman, B, Inzucchi, SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
20. Heerspink, HJL, Johnsson, E, Gause-Nilsson, I, Cain, VA, Sjöström, CD, Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 18 (2016), 590–597.
21. Petrykiv, SI, Laverman, GD, de Zeeuw, D, Heerspink, HJL, The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes Obes Metab 19 (2017), 1363–1370.
22. Heerspink, HJL, Stefansson, BV, Chertow, GM, et al. Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant 35 (2020), 274–282.
23. AstraZeneca. Farxiga phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease. https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html, March 30, 2020. (Accessed 17 April 2020)
24. Layton, AT, Vallon, V, SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol 314 (2018), F969–F984.
25. Sayour, AA, Korkmaz-Icöz, S, Loganathan, S, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med, 17, 2019, 127.
26. Uthman, L, Homayr, A, Juni, RP, et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem 53 (2019), 865–886.
27. Heerspink, HJL, Perkins, BA, Fitchett, DH, Husain, M, Cherney, DZI, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
28. Li, J, Woodward, M, Perkovic, V, et al. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail 8 (2020), 57–66.
29. Cherney, DZI, Cooper, ME, Tikkanen, I, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 93 (2018), 231–244.
30. McMurray, JJV, Solomon, SD, Inzucchi, SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 (2019), 1995–2008.